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S U M M A R Y
Objectives: Ross River is an emerging mosquito-borne disease in the Western Paciﬁc. Ross River virus
(RRV) circulation has been sporadically reported in some Paciﬁc Island Countries and Territories but
never in French Polynesia. To determine if RRV has circulated locally among the French Polynesian
population, we conducted a seroprevalence study on blood donors.
Methods: Sera of 593 blood donors were collected from July 2011 to October 2013 and tested by ELISA for
the presence of RRV-speciﬁc Immunoglobulin G (IgG) antibodies.
Results: A total of 204 (34.40%) blood donors were found seropositive for RRV. Among the 132 blood
donors that were born in French Polynesia and had never travelled abroad, 56 (42.42%) had RRV-speciﬁc
IgGs.
Discussion: Our results support the existence of autochthonous RRV transmission and suggest that this
pathogen has silently circulated in French Polynesia. These ﬁndings raise the question of possible
undetected circulation of RRV in other Paciﬁc Island Countries and Territories.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
French Polynesia (FP) is a French overseas territory of about
270,000 inhabitants in the Southeast Paciﬁc, and one of the
22 Paciﬁc Islands Countries and Territories (PICTs). Arthropod-
borne virus (arbovirus) infections are major public health concern
in the PICTs, with dengue virus (DENV), a Flavivirus of the
Flaviviridae family, as the most common circulating and wide-
spread arbovirus.1 In FP, DENV outbreaks have been recorded since
the 40s.1–4 DENV used to be the only arbovirus isolated until
October 2013 when FP experienced the largest outbreak of Zika
virus (ZIKV) ever reported,5,6 followed by an outbreak of
chikungunya virus (CHIKV) that started in October 2014.7 These
two viruses, belonging respectively to Flavivirus and Alphavirus* Corresponding author: Maite Aubry, Institut Louis Malarde´, PO BOX 30,
98713 Papeete, Tahiti, French Polynesia.
Tel./fax: +689 40 416 460/(689) 40 431 590.
E-mail address: maubry@ilm.pf (M. Aubry).
http://dx.doi.org/10.1016/j.ijid.2015.06.005
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).genera, have also been recently involved in outbreaks in other
PICTs.6,8,9 Other arboviruses have been reported in PICTs, but not in
FP, such as Japanese encephalitis virus (JEV)10 and Ross River virus
(RRV).11
RRV is an arbovirus belonging to the Alphavirus genus of the
Togaviridae family.12 It was ﬁrst isolated from Aedes vigilax
mosquitoes in Australia in 195913 and further from more than
30 mosquito species.12 The most common clinical manifestations
of RRV infections are fever, arthralgia and rash. Asymptomatic
infections range from 55 to 75%.12,14–16 The ﬁrst reports of unusual
epidemics of ‘‘pain, skin eruption and general manifestations’’
thought to have been due to RRV occurred in 1928 in New South
Wales, Australia.17,18 A large RRV outbreak occurred in the Paciﬁc
in 1979-1980 with over 500.000 cases reported,16 and affected
several PICTs including Fiji, Cook Islands, American Samoa, New
Caledonia, Wallis & Futuna, and Vanuatu.14,19–23 In FP, due to the
neighbouring RRV epidemics, patients presenting with a ‘‘dengue
like syndrome’’ were routinely tested for RRV in addition to DENV
between April and August 1980 then sporadically until February
1984. Although no RRV infection was detected during this periodciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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After the 1979-1980 outbreak, RRV apparently disappeared from
the PICTs. However, cases of RRV infections were subsequently
reported from travelers returning from Fiji: 2 Canadian travelers,
respectively in 2003 and 2004,24 and 5 New Zealand travelers,
respectively in 1997, 2000, 2001, 2003 and 2009.16 Evidence of RRV
infections were also found among residents of Papua New
Guinea.25
To date, few data are available about the circulation, incidence
and prevalence of RRV in the Paciﬁc. To our knowledge,
13 serosurveys have been conducted for RRV in the region.12,14,20
Among the studies performed in Australia,12 seropositivity ranged
from 8% for sera collected in North and Southeast Queensland,
Darwin and Northern territory area in 1974-197526 to up to 55% for
sera collected from aboriginal communities in North Queensland
and Northern territory in 1966-1971.27 In a serosurvey conducted
by Tesh et al. in several PICTs,28 evidence of RRV infections was
found among populations sampled in Papua New Guinea between
1960 and1969 and in Solomon Islands between 1960 and 1966,
with rates of RRV seropositivity among localities ranging from 10%
to 64% and 1% to 17%, respectively. In contrast, no RRV antibodies
were found in sera collected in Vanuatu in 1963 and 1972, New
Caledonia in 1963, Palau in 1961 and 1974, and American Samoa in
1962. In a study further conducted in American Samoa, 43.8% of the
people sampled at the end of the 1979-1980 RRV outbreak had
evidence of RRV infection, whereas those previously sampled in
1972 had no RRV antibodies.20 In Fiji, seroprevalence was over 90%
in some communities after the RRV outbreak in 1979-1980.14 In
the only study conducted among blood donors, seroprevalence for
RRV antibodies was 8.4% from the 2,952 sera collected in South
Australia in 1992.29 To our knowledge, except for Australia where
RRV is the most common and widespread arboviral disease with
about 5,000 cases notiﬁed annually,11,30 and to a lesser extent for
Fiji,16,24 there are no recent data about circulation of RRV in the
Paciﬁc area.
Due to the incidence of RRV infections in Australia and frequent
population movements across the Paciﬁc region, the risk of
emergence of this virus in PICTs, as happened in the early 80s,14,19–
23 is high. More recently, the detection of sporadic cases of RRV
infections from Fiji 16,24 shows that this pathogen remains a serious
threat to the PICTs. In order to determine if RRV has already beenFigure 1. Circulation of Ross river virus in the Paciﬁc. Countries with reported Ross River introduced and has circulated in FP, we conducted a serological
survey on 593 blood donors sera collected from July 2011 to
October 2013.
2. Materials and Methods
2.1. Participants
Blood donors were recruited by the French Polynesian blood
bank centre (Tahiti, FP). All blood donors lived in Tahiti, the most
inhabited island of FP, and were over 18 years old. Written consent
for the use of a serum sample for serological testing was obtained
before blood collection for all the blood donors included in this
study. Volunteers to blood donation reporting a ‘‘dengue like
syndrome’’ in the past 3 months, or any symptoms of acute or
recent infection, were excluded from blood donation. None of the
blood donors has been sampled speciﬁcally for the purpose of this
study. A medical questionnaire was completed by the physician of
the blood bank center before blood collection, in accordance with
the recommendations for blood donation. The number of years of
residence in FP and the past history of travel outside FP were
recorded for all blood donors.
A total of 593 blood donors recruited from July 2011 to October
2013 were included in this study. Based on their travel history,
blood donors were divided into 3 groups: group 1 is composed of
residents who were born in FP and have never travelled abroad
(132 blood donors); group 2 of residents who were born in FP and
have travelled at least once abroad (290 blood donors); and group
3 of immigrants (171 blood donors). Within groups 2 and 3, blood
donors reporting past travel in countries with or without reported
RRV autochthonous infections (Figure 1) were separated in
2 subgroups, a and b respectively (Table 1).
2.2. Sample Collection
Blood samples for serological testing were collected in BD
Vacutainer1 Blood Collection tubes and stored at + 4 8C for
maximum 1 day at the blood bank centre before shipment to the
‘‘Institut Louis Malarde´’’ (ILM), Tahiti, FP. At ILM, blood samples
were centrifuged for 15 minutes at 1,300 g then sera were
retrieved and frozen at – 20 8C until processing.virus autochthonous infections are circled in red. French Polynesia is circled in blue.
Table 1
Characteristics of the blood donors included in the study
Blood donors Born in FP Immigrants Total
Group 1 Group 2a Group 2b Total group 2 Group 3a Group 3b Total group 3
Number 132 145 145 290 101 70 171 593
% 22.26 24.45 24.45 48.90 17.03 11.80 28.84 100
Age
Range 18-59 18-69 18-63 18-69 19-75 19-72 19-75 18-75
Mean 32.80 38.13 31.93 35.03 44.78 41.11 43.28 36.91
Median 32.00 37.00 29.00 33.00 46.00 41.00 42.00 36.00
Years of residence in FP
Range 18-59 12-69 15-63 12-69 0-49 0-50 0-50 0-69
Mean 32.80 37.47 31.65 34.56 17.16 11.41 14.81 28.47
Median 32.00 36.00 29.00 32.00 16.00 7.50 12.00 27.00
Group 1: residents who were born in FP and have never travelled abroad; group 2a: residents who were born in FP and have travelled at least once in a country with reported
RRV infections; group 2b: residents who were born in FP and have travelled at least once but in countries without reported RRV infections; group 3a: immigrants who have
travelled at least once in a country with reported RRV infections; group 3b: immigrants who have travelled at least once but in countries without reported RRV infections.
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Serum samples were tested for the presence of immunoglobulin
G class antibodies (IgGs) against RRV by indirect ELISA using
recombinant antigens from RRV. Given that CHIKV has circulated
in the PICTs since 2011 and is antigenically related to RRV,
recombinant antigens from CHIKV were also used to test serum
samples.
Recombinant antigens were produced in Drosophila S2 cells
using the Drosophila S2 expression system (Life Technologies,
USA). The synthetic genes (GeneCust, Luxembourg) encoding the
soluble ectodomain of the envelope E2 glycoprotein (sE2) from
RRV strain QML 1 (GenBank accession no. GQ433354) or CHIKV La
Reunion strain 06-49 (GenBank accession no. AM258994) were
cloned into the shuttle vector pMT/BiP/His A in which the SNAP-
tag sequence (Covalys Biosciences AG, Switzerland) had been
initially inserted as a stabilizing protein. The resulting plasmids
encoding either the chimeric protein RR.sE2-SNAP or CHIK.sE2-
SNAP were transfected into S2 cells to establish stable cell lines S2/
RR.sE2-SNAP, and S2/CHIK.sE2,31 according to the manufacturer’s
recommendations (Life Technologies, USA). After a 10-days
cadmium induction of the stable S2 cell lines grown in 1-Liter
spinner, cell supernatants were recovered and secreted soluble
His-tagged recombinant viral antigens were puriﬁed on chelating
and size-exclusion chromatography columns. The protein amounts
of highly puriﬁed RR.sE2-SNAP and CHIK.sE2-SNAP were deter-
mined using a BCA protein assay kit (Thermo Scientiﬁc, USA),
according to manufacturer’s instructions. At least 50 mg of each
recombinant viral antigen (concentration: 0.5 to 1 mg/ml) were
obtained from a single batch of 1-L of S2 cell culture. The samples
of puriﬁed RR.sE2-SNAP and CHIK.sE2-SNAP proteins were kept at
-80 8C.
2.4. Protocol of indirect ELISA
For the capture of anti-RRV and anti-CHIKV IgGs, RR.sE2-SNAP,
CHIK.sE2-SNAP, and antigen control (SNAP) were diluted at the
ﬁnal concentration of 2 mg/mL in phosphate buffer saline (PBS,
Biome´rieux, France), and 100 mL of protein sample were coated in
96-well plates overnight at +4 8C. After incubation, antigen sample
was removed and wells were blocked with PBS containing 3% of
skimmed milk (Re´gilait, France) and 1% of sodium azide (Merck,
Germany). Sera of participants, as well as negative and positive
control sera, were diluted 1:400 in PBS with 3% skimmed milk,
0.05% Tween 20 and 1% sodium azide. Then, each diluted serum
was added in 2 wells containing either RR.sE2 or CHIK.sE2
recombinant antigens, and in 2 wells containing only SNAP
proteins. Plates were incubated for 1 hour at 41 8C andsubsequently washed using PBS with 0.05% Tween 20 (Merck,
Germany). Peroxidase-conjugated goat anti-human IgG antibodies
(Jackson ImmunoResearch, USA) were added in all wells at a
dilution of 1:10 000 in PBS with 3% skimmed milk and 0.05% Tween
20. Plates were incubated for 1 hour at 41 8C and washed before
addition of peroxidase substrate tetramethylbenzidine (TMB, KPL,
USA). Plates were stored at room temperature in the dark for
5 minutes and the enzymatic reaction between the peroxidase and
its substrate was stopped by the addition of TMB Stop Solution
(KPL, USA). The absorbance was read at a wavelength of 450 nm
(OD450) using a microplate photometer (Thermo Scientiﬁc, USA).
Sera found positive for RRV IgGs using recombinants antigens
were also tested using the kit Panbio Ross River Virus IgG ELISA
(Panbio diagnostics, USA), following manufacturer’s recommenda-
tions.
2.5. Serological analysis
For each serum, average absorbance was calculated using the
OD450 values measured in the 2 wells containing the same
recombinant antigen or SNAP proteins. Speciﬁc absorbance was
then determined by deducting the mean absorbance value
obtained with SNAP to the mean absorbance value found for each
recombinant antigen. Sera with a speciﬁc absorbance value 
0.2 were considered positive for the presence of IgGs against the
virus tested.
2.6. Statistical analysis
To assess the impact of age and travel history on RRV
seroprevalence among participants, Fisher’s test was performed
using the GraphPad Prism 6 version 6.03 software. P values less
than 0.05 were considered as statistically signiﬁcant.
2.7. Ethics Statement
The recruitment of participants and processing of blood
samples were conducted in accordance with the Ethics Committee
of French Polynesia under reference n860/CEPF (06/27/2013).
Blood sample and personal data of each participant were
anonymized at the French Polynesian blood bank centre before
sending to ILM.
3. Results
Among the 593 blood donors, 204 (34.40%), 18 (3.03%) and 10
(1.69%) were found seropositive for RRV, CHIKV or both viruses
IgGs, respectively (Table 2). Seroprevalence in different groups and
Table 2
Seropositivity for RRV and CHIKV in each group of blood donors
Blood donors Born in FP Immigrants Total
Group 1 Group 2a Group 2b Total group 2 Group 3a Group 3b Total group 3
Seropositive for RRV
Total 56 (2)a 49 (6) 52 (5) 101 (11) 32 (1) 15 (0) 47 (1) 204 (14)
% 42.42 33.79 35.86 34.83 31.68 21.43 27.48 34.40
Seropositive for CHIKV
Total 2 6 4 10 6 0 6 18
% 1.51 4.14 2.76 3.45 5.94 0 3.51 3.03
Seropositive for both RRV and CHIKV
Total 1 4 3 7 2 0 2 10
% 0.76 2.76 2.07 2.41 1.98 0.00 1.17 1.69
a Number of blood donors tested positive for RRV with the kit Panbio Ross River Virus IgG Elisa.
Table 3
Seropositivity for RRV according to the year of birth or the number of years of residence for blood donors that have never travelled in countries with reported RRV infections
Blood donors seropositive for RRV Group 1 Group 2b Group 3b
Born in FP
Born before 1981 33/70 (47.14%) 28/68 (41.17%) –
Born from 1982 to 1987 8/20 (40.00%) 12/37 (32.43%) –
Born from 1988 to 1992 10/27 (37.03%) 10/31 (32.25%) –
Born after 1993 5/15 (33.33%) 2/9 (22.22%) –
Total born after 1981 23/62 (37.09%) 24/77 (31.16%) –
Total born before and after 1981 56/132 (42.42%) 52/145 (35.86%) –
Immigrants
Arrived in FP before 1981 – – 3/8 (37.5%)
Arrived in FP between 1982-2000 – – 8/20 (40.00%)
Arrived in FP between 2001-2005 – – 2/8 (25.00%)
Arrived in FP between 2006-2013 – – 2/34 (5.88%)
Total arrived in FP after 1981 – – 12/62 (19.35%)
Total arrived in FP before and after 1981 – – 15/70 (21.43%)
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RRV and it ranged from 0% (group 3b) to 5.94% (group 3a) for
CHIKV. Percentages of RRV seropositivity were not signiﬁcantly
different between groups except for group 3b against groups 1 and
2b (P values were 0.0032 and 0.0408, respectively). Among the
204 blood donors seropositive for RRV IgGs, 14 were also found
positive using the kit Panbio Ross River Virus IgG ELISA.
Seroprevalence for RRV according to the year of birth or the
length of stay in FP of blood donors that have never travelled in
areas with known circulation of RRV is reported in Table 3. Among
blood donors born after 1981 belonging to groups 1 and 2b, 37.09%
and 31.16% were seropositive for RRV, respectively. In the two
groups, the rate of positivity for RRV IgGs increased with age.
Among blood donors of group 3b who arrived in FP during the
years 1982-2000, 2001-2005 and 2006-2013, 40%, 25% and 5.88%
were seropositive for RRV, respectively.
4. Discussion
Arboviruses are emerging pathogens in Oceania8,32 and, except
for DENV, few data are available about their circulation, incidence
and prevalence in the region. In particular, the spread of RRV in the
Paciﬁc region is unknown. In the present study, sample collection
was conducted in FP from July 2011 to early October 2013. Even if
the ﬁrst CHIKV outbreak in FP was recorded in October 2014,
CHIKV had begun circulating in other PICTs from 2011.8
Consequently, a previous silent circulation of CHIKV in FP cannot
be excluded. To insure that the detection of RRV IgGs was not due
to cross-reaction of RRV recombinant antigens with CHIKV
antibodies resulting from a non-detected previous infection, all
sera were tested for the presence of CHIKV IgGs, in addition to RRV
IgGs. The low rate of immunization against CHIKV measured
among blood donors (3.03%) suggests that the virus did notactively circulate in FP before 2014. This hypothesis is supported
by the large magnitude of the CHIKV outbreak that started in
October 2014, with at least 25% of the population estimated to
have been infected.33 Moreover, the small number of sera found
positive for both RRV and CHIKV IgGs (10/593) suggests the
absence or limited cross-reactions between the two Alphaviruses
with our ELISA assay.
The 204 sera found positive for RRV IgGs using recombinant
antigens were also tested with a commercial serological assay (kit
Panbio Ross River Virus IgG ELISA), and 14 (6.86%) of them were
found positive with both assays, conﬁrming the circulation of RRV
in FP. Discordant results between in-house and commercial
serological tests have already been reported for other arboviruses.
For instance, two commercial ELISA kits evaluated for the detection
of CHIKV IgGs in serum samples previously tested positive with in-
house ELISAs from 2 National Reference Centers for Arboviruses
showed sensitivities of 52% and 88%.34 Moreover, when comparing
the performance of several serological tests for detecting JEV-
speciﬁc IgGs in 29 vaccinated children, the in-house assay detected
neutralizing antibodies in all children whereas the commercial
ELISA assay showed no positive reaction.35 In another study
conducted on serum samples from 100 persons vaccinated against
JEV, only 6.6% of the sera found positive with the in-house assay
were also detected positive using a commercial IgG ELISA test.36
The discrepancy between the results obtained with laboratory and
commercial assays may be related to the cut-off used. For a
diagnosis purpose (commercial kit), the cut-off is high because
speciﬁcity is preferred to sensitivity. Moreover, diagnostic kits are
dedicated to the detection of recent rather than past infections and
should not be used to screen general population, which is the
purpose of seroprevalence studies. According to the manufac-
turer’s protocol, the cut-off of the commercial kit used in our study
was determined on an Australian population and may require
M. Aubry et al. / International Journal of Infectious Diseases 37 (2015) 19–24 23adjustment depending on the population analyzed. Consequently,
the cut-off of the commercial assay should be adapted for the
analysis of the serological results obtained from the French
Polynesian population.
The overall rate of RRV seropositive blood donors found in our
study was surprisingly high (34.40%) given that RRV infection cases
had never been reported in FP. The absence of signiﬁcant difference
in prevalence between blood donors who were born in FP and have
travelled or not in areas with or without RRV reported infections
(groups 1 and 2), suggests that they have been infected in FP. The
high rates of RRV seropositivity found among blood donors who
were born in FP after 1981, whatever they had never travelled
abroad (group 1, 37.09%) or had travelled only in areas without
RRV reported cases (group 2b, 31.16%), support the idea that RRV
has circulated in FP after the large outbreak that occurred in 1979-
1980 in the PICTs. The lowest (21.43%) and highest (42.42%) RRV
seroprevalence rates are found for the immigrant group that is
supposed not to have been exposed elsewhere than in FP (group
3b) and for the group of residents who were born in FP and have
never travelled abroad (group 1), respectively, and are signiﬁcantly
different between the two groups (P=0.0032). Together with the
median time of residence in FP for the immigrants (7.50 years)
which is 4 times lower than the one found for the blood donors
born in FP (32.00 years), these data suggest that the increase in RRV
seroprevalence is linked to the time of residence in FP. The increase
with age of the acquisition of RRV IgGs among the residents born in
FP and that could have been infected only locally (goups 1 and 2b)
is consistent with a silent continuous circulation of RRV during the
last decades. This is conﬁrmed by the detection of 12 RRV
seropositive blood donors among immigrants who arrived in FP
between 1982-2013 and who have never travelled in countries
with reported RRV infections (group 3b). The ﬁnding that RRV has
circulated in FP is concordant with the presence of several
mosquito species that can potentially transmit the virus, including
Aedes aegypti, Aedes polynesiensis, Culex annulirostris, Culex
quinquefasciatus and Culex sitiens.12,19,37–41
RRV may have circulated in FP without being detected for
several reasons. The main one is that 55% to 75% of RRV infections
are asymptomatic,12,14–16 and many symptomatic patients have
mild symptoms that may not require to seek medical attention. In
addition, RRV infections can have clinical presentations similar to
DENV infections. However, with laboratory capacities for arbo-
viruses detection mainly focused on DENV, patients presenting
with a ‘‘dengue like syndrome’’ but tested negative for DENV are
not systematically investigated for other arboviruses. At last, virus
isolation is rarely achieved, probably because RRV does not persist
beyond the early stages of disease,12 which may explain why
despite laboratory diagnosis, no RRV infectious cases were
detected in FP between 1980-1984.
Only adults were tested in this study but since most infections
occur between the ages of 20 and 60, peaking between 30 and
40,16,42 it should be relevant. Thus, despite the exclusion of
children and discrepant results in the percentage of RRV positive
blood donors depending on serological methodology used, we can
conclude to a silent circulation of RRV in FP. Irrefutable evidence of
autochthonous RRV transmission in FP would require the isolation
of the virus or of its RNA from a resident with no recent travel
history. Attempts to isolate RRV will be performed in a second
study on sera collected from patients presenting with symptoms
suggestive of an arbovirus infection and tested negative for DENV,
ZIKV and CHIKV.
Like RRV, it is possible that other arboviruses may also have
circulated in FP and in other PICTs without being detected. Indeed,
the occurrence of West Nile virus or JEV introductions respectively
from the USA and Japan are possible since many PICTs have direct
and frequent ﬂights from these countries, and several mosquitospecies established in the PICTs may transmit these viruses.38 Due
to the growing risk of emergence of new arboviruses in the Paciﬁc,
joint efforts should be done to improve local and regional
surveillance,43 as well as vector control.
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